Key result
New agents for pulmonary arterial hypertension improve symptoms and reduce pulmonary resistance, necessitating early diagnosis and comprehensive multidisciplinary management.
Highlights the need for early diagnosis, improved access to new therapies, and multidisciplinary centers of excellence for managing pulmonary arterial hypertension, particularly in Australia.
Supports early PAH diagnosis efforts; leaves open optimal multidisciplinary implementation in Australia.
Pulmonary arterial hypertension (PAH) is a heterogeneous condition with a wide range of causes. The diagnosis is often delayed or missed. PAH is covert in its early stages, when its detection and treatment should have the most impact. Access in Australia to effective PAH therapies has lagged behind that in other affluent countries. New agents for PAH, now becoming available, improve symptoms and reduce pulmonary resistance, with some demonstrating an ability to reverse remodelling of the right ventricle. Best management of PAH is comprehensive and multidisciplinary. Centres of excellence are needed in geographically strategic areas. Aggressive efforts must be made to diagnose PAH and to facilitate access to effective therapies.
No takes yet. Share an insight, caveat, or question.
Keogh et al. (2003) conducted a review in Pulmonary arterial hypertension. New agents for PAH was evaluated. New agents for pulmonary arterial hypertension improve symptoms and reduce pulmonary resistance, necessitating early diagnosis and comprehensive multidisciplinary management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: